Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Frontline HL news: the debate continues

Graham Collins • 18 May 2020
Hodgkin Lymphoma Brentuximab vedotin Nivolumab

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, highlights some of the current debates in frontline Hodgkin lymphoma from data presented at BSH 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Graham Collins

1:19
Mechanism of action of BTK degraders and insights into NX-5948
Graham Collins • 16 Jun 2023
1:15
The benefits of glofitamab in R/R DLBCL post-CAR-T therapy
Graham Collins • 16 Jun 2023
1:30
The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trials
Graham Collins • 16 Jun 2023
1:56
The future of bispecific antibodies in the treatment and management of R/R follicular lymphoma
Graham Collins • 16 Jun 2023

Related Videos

2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:50
Results of the EuroNet-PHL-C1 trial: omission of radiotherapy in children and adolescents with cHL
Christine Mauz-Körholz • 8 Dec 2023
1:17
KEYNOTE-667: pembrolizumab plus COPDAC-28 for high-risk cHL with slow early response to OEPA
Christine Mauz-Körholz • 8 Dec 2023
0:52
Managing late effects of treatment in pediatric patients with Hodgkin lymphoma
Christine Mauz-Körholz • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals